Braxia Scientific Corp.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BRAXF research report →
Companywww.braxiascientific.com
Braxia Scientific Corp. operates as a medical research company with clinics that provide ketamine treatments for persons with depression and related disorders. It is also involved in the research activities related to discovering and commercializing novel drugs and delivery methods; and developing ketamine and psilocybin derivatives and other psychedelic products from its IP development platform.
- CEO
- Peter Rizakos
- IPO
- 2020
- HQ
- Mississauga, ON, CA
Price Chart
Valuation
- Market Cap
- $28.33K
- P/E
- -0.09
- P/S
- 0.75
- P/B
- 0.71
- EV/EBITDA
- -0.01
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 9.12%
- Op Margin
- -397.00%
- Net Margin
- -697.48%
- ROE
- -248.72%
- ROIC
- -408.30%
Growth & Income
- Revenue
- $1.88M · 26.70%
- Net Income
- $-13,141,704 · -8.30%
- EPS
- $-0.06 · 16.91%
- Op Income
- $-7,480,135
- FCF YoY
- -82.71%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.31
- Avg Volume
- 267.73K
Get TickerSpark's AI analysis on BRAXF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our BRAXF Coverage
We haven't published any research on BRAXF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BRAXF Report →